South Korea · Delayed Price · Currency is KRW Boditech Med Statistics
Total Valuation
Boditech Med has a market cap or net worth of KRW 232.34 billion. The enterprise value is 225.27 billion.
| Market Cap | 232.34B |
| Enterprise Value | 225.27B |
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | Mar 31, 2026 |
Share Statistics
Boditech Med has 20.34 million shares outstanding. The number of shares has decreased by -1.22% in one year.
| Current Share Class | 20.34M |
| Shares Outstanding | 20.34M |
| Shares Change (YoY) | -1.22% |
| Shares Change (QoQ) | -0.97% |
| Owned by Insiders (%) | 30.04% |
| Owned by Institutions (%) | 1.07% |
| Float | 14.12M |
Valuation Ratios
The trailing PE ratio is 10.47.
| PE Ratio | 10.47 |
| Forward PE | n/a |
| PS Ratio | 1.43 |
| PB Ratio | 0.95 |
| P/TBV Ratio | 1.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 10.52 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.99, with an EV/FCF ratio of -20.61.
| EV / Earnings | 9.52 |
| EV / Sales | 1.39 |
| EV / EBITDA | 5.99 |
| EV / EBIT | 8.18 |
| EV / FCF | -20.61 |
Financial Position
The company has a current ratio of 5.24, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.24 |
| Quick Ratio | 3.28 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.46 |
| Debt / FCF | -1.62 |
| Interest Coverage | 70.36 |
Financial Efficiency
Return on equity (ROE) is 10.22% and return on invested capital (ROIC) is 11.21%.
| Return on Equity (ROE) | 10.22% |
| Return on Assets (ROA) | 6.75% |
| Return on Invested Capital (ROIC) | 11.21% |
| Return on Capital Employed (ROCE) | 11.21% |
| Weighted Average Cost of Capital (WACC) | 6.41% |
| Revenue Per Employee | 299.62M |
| Profits Per Employee | 43.72M |
| Employee Count | 541 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, Boditech Med has paid 3.90 billion in taxes.
| Income Tax | 3.90B |
| Effective Tax Rate | 14.04% |
Stock Price Statistics
The stock price has decreased by -22.31% in the last 52 weeks. The beta is 0.45, so Boditech Med's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -22.31% |
| 50-Day Moving Average | 12,324.00 |
| 200-Day Moving Average | 13,450.10 |
| Relative Strength Index (RSI) | 47.60 |
| Average Volume (20 Days) | 72,085 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Boditech Med had revenue of KRW 162.09 billion and earned 23.65 billion in profits. Earnings per share was 1,091.00.
| Revenue | 162.09B |
| Gross Profit | 95.53B |
| Operating Income | 28.94B |
| Pretax Income | 27.78B |
| Net Income | 23.65B |
| EBITDA | 39.00B |
| EBIT | 28.94B |
| Earnings Per Share (EPS) | 1,091.00 |
Balance Sheet
The company has 37.72 billion in cash and 17.75 billion in debt, with a net cash position of 19.97 billion or 981.80 per share.
| Cash & Cash Equivalents | 37.72B |
| Total Debt | 17.75B |
| Net Cash | 19.97B |
| Net Cash Per Share | 981.80 |
| Equity (Book Value) | 244.18B |
| Book Value Per Share | 10,770.92 |
| Working Capital | 99.18B |
Cash Flow
In the last 12 months, operating cash flow was 22.08 billion and capital expenditures -33.01 billion, giving a free cash flow of -10.93 billion.
| Operating Cash Flow | 22.08B |
| Capital Expenditures | -33.01B |
| Depreciation & Amortization | 10.06B |
| Net Borrowing | 5.41B |
| Free Cash Flow | -10.93B |
| FCF Per Share | -537.31 |
Margins
Gross margin is 58.94%, with operating and profit margins of 17.85% and 14.59%.
| Gross Margin | 58.94% |
| Operating Margin | 17.85% |
| Pretax Margin | 17.14% |
| Profit Margin | 14.59% |
| EBITDA Margin | 24.06% |
| EBIT Margin | 17.85% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.35%.
| Dividend Per Share | 150.00 |
| Dividend Yield | 1.35% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 13.81% |
| Buyback Yield | 1.22% |
| Shareholder Yield | 2.58% |
| Earnings Yield | 10.18% |
| FCF Yield | -4.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 5, 2017. It was a forward split with a ratio of 1.1.
| Last Split Date | Apr 5, 2017 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Boditech Med has an Altman Z-Score of 7.56 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.56 |
| Piotroski F-Score | 6 |